Fig 1: A representative example of methylation-specific PCR analysis for the suppressor of fused gene promoter in term placentas from physiologic pregnancies (CP) and term placentas from pregnancies complicated with IUGR. IUGR1 and IUGR2 are samples from different patients. IUGR1 is a representative example of the unmethylated promoter of the SUFU gene in IUGR placentas. IUGR2 is one sample of IUGR placenta with the presence of methylated promoter of the SUFU gene. CP, control placenta; H2O, water, negative control; IUGR, intrauterine growth restriction; M, methylated reaction; MC, methylated human control, positive control for methylated reaction; UM, unmethylated reaction; UMC, unmethylated human control, positive control for unmethylated reaction.
Fig 2: WNT5A, SUFU and CTNNB1 mRNA expression in IUGR vs. control placental tissue normalized to GAPDH and relative to control tissue. CTNNB1, catenin ß1; IUGR, intrauterine growth restriction; SUFU, suppressor of fused.
Fig 3: Membrane cholesterol promoted the proliferation of GH3 cells by activating the Hh signaling pathway. a A schematic showing the process via which cholesterol promotes cell proliferation by activating the Hh signaling pathway. The Mß-CD/CHO complex (CHO) is an agonist and vismodegib is an antagonist that binds and modulates the activity of SMO. SMO RNAi was used to knock down SMO expression. Forskolin blocked signaling by elevating cAMP levels, which increased PKA activity. b Vector GH3 cells were treated with Mß-CD (20 µg/ml) or the Mß-CD/CHO complex (20 µg/ml) for 48 h. Protein expression levels of PKA, SUFU, GLI1, BCL2 and CCND1 in the four groups (Vector, SCP2-OE, Vector + Mß-CD and Vector + Mß-CD/CHO) were assessed by Western blotting. c SCP2-OE GH3 cells were treated with vismodegib (VIS, 50 µM) and Vector GH3 cells were treated with the Mß-CD/CHO complex (20 µg/ml) in the presence or absence of vismodegib (50 µM) for 0, 24, 48 or 72 h. Cell proliferation in the four groups (SCP2-OE, SCP2-OE + VIS, Vector + Mß-CD/CHO and Vector + Mß-CD/CHO + VIS) at different time points was assessed by a CCK-8 assay (n = 6, ± SEM). Protein expression levels of PKA, SUFU, GLI1, BCL2 and CCND1 at 48 h were assessed by Western blotting. Cell apoptosis and the cell cycle at 48 h were analyzed using flow cytometry (n = 3, ± SEM). d SCP2-OE and wild-type GH3 cells were infected with negative control vector (NC) or SMO shRNA vector (SMO-2 and SMO-3) for 48 h, and the transfected wild-type GH3 cells were incubated with the Mß-CD/CHO complex (CHO, 20 µg/ml) for another 0, 24, 48 or 72 h. Cell proliferation in the six groups (SCP2-OE + NC, SCP2-OE + SMO-2, SCP2-OE + SMO-3, NC+ CHO, SMO-2 + CHO and SMO-3 + CHO) at different time points were assessed by a CCK-8 assay (n = 6, ± SEM). Protein expression levels of PKA, SUFU, GLI1, BCL2 and CCND1 at 48 h were examined by Western blotting. Cell apoptosis and the cell cycle at 48 h were analyzed using flow cytometry (n = 3, ± SEM). e SCP2-OE GH3 cells were treated with forskolin (FOR, 25 µM) and Vector GH3 cells were treated with the Mß-CD/CHO complex (20 µg/ml) in the presence or absence of forskolin (25 µM) for 0, 24, 48 or 72 h. Cell proliferation in the four groups (SCP2-OE, SCP2-OE + FOR, Vector + Mß-CD/CHO and Vector + Mß-CD/CHO + FOR) at different time points was assessed by a CCK-8 assay (n = 6, ± SEM). Protein expression levels of PKA, SUFU, GLI1, BCL2 and CCND1 at 48 h were assessed by Western blotting. Cell apoptosis and the cell cycle at 48 h were analyzed using flow cytometry (n = 3, ± SEM). An unpaired t-test was used to assess statistical significance. *P < 0.05; **P < 0.01; ***P < 0.001
Fig 4: Boxplots of WNT5A, ß-catenin and SUFU protein expression in IUGR and normal (control) placentas in trophoblasts, endothelium and stroma. 0, no staining observed; 1, <10% cells were stained; 2, 10–50% cells were stained; and 3, >50% cells were stained. Asterisks denote extreme outliers, while small circles denote outliers. IHC, immunohistochemistry; IUGR, intrauterine growth restriction; n.s., not statistically significant; SUFU, suppressor of fused.
Fig 5: Ciliary expression of SHH signaling componentsControl and INPP5ED477N/D477N organoids were immunostained with the indicated markers.(A–H) SMO was expressed in a higher proportion of cilia and at higher levels in INPP5ED477N/D477N organoids.(I–P) There were no significant changes either in the proportion of positive cilia or in the expression levels for SUFU.(Q–X) GLI2 accumulated in mutant cilia.Statistical data are presented as means ± 95% confidence intervals (CIs); unpaired t tests (D, L, and T) and Mann-Whitney tests (H, P, and X); n = 3 (control) and n = 2 (mutant) lines for (D), (L), and (T); n = 45 (control) and n = 30 (mutant) cilia from three and two different lines, respectively (H, P, and X); *p < 0.05; **p < 0.01; ****p < 0.0001. Scale bar, 2.5 µm. See also Figures S6 and S7.
Supplier Page from Proteintech Group Inc for SUFU antibody